Key Takeaways The obesity space has garnered much of the spotlight over the past year due to the sizeable and still underpenetrated market opportunity. Smaller biotechs like Structure Therapeutics (GPCR) and Viking Therapeutics (VKTX) are also developing GLP-1-based therapies to challenge the incumbents. Eli Lilly's Foundayo approval introduces a direct oral GLP-1 rival to Novo Nordisk's Wegovy pill. LLY's strong execution and Zepbound's rapid share gains highlight its growing obesity market momentum. Novo ...